Boan Biotech (6955.HK) today announced its 2023 financial results and latest developments.High-quality development delivering remarkable performanceDuring the reporting period, the company's reven...
Yantai, March 8, 2024 – Boan Biotech (6955.HK) today announced the completion of a Phase 3 clinical trial (a comparative study of efficacy, safety, and immunogenicity) for its Dulaglutide Inject...
The platform can enhance the efficiency of biologics development by creating stable and highly expressed cell linesYantai, China, January 30, 2024 -- Boan Biotech (6955.HK) has entered into an agreeme...